Tag: Society of Nuclear Medicine and Molecular Imaging
SNMMI Patient Education Day – Hybrid (In-Person and Virtual)
The Society of Nuclear Medicine and Molecular Imaging will offer a special Patient Education Day on Sunday, June 12 as part of its 2022 Annual Meeting. This free event offers patients and caregivers a unique opportunity to learn about the role of nuclear…
READ MORE
FDA Approves LUTATHERA® for Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors
BREAKING NEWS: On January 26, 2018 the US Food and Drug Administration approved LUTATHERA® marking the first time a radioactive drug, or radiopharmaceutical, has been approved for the treatment of gastroenteropancreatic neuroendocrine tumors …
READ MORE
Gallium 68 PET/CT Scanning for Neuroendocrine Tumors — Information and Locations (updated January 26, 2019)
The US Food and Drug Administration’s (FDA) June 1, 2016 approval of the Gallium-68 PET/CT DOTATATE scan using NETSPOT® heralded a new age of nuclear imaging for neuroendocrine tumors in the United States.
PLEASE SCROLL DOWN FOR A STATE-BY STATE LIST … READ MORE One Step Closer in the US to Peptide Receptor Radionuclide Therapy, PRRT, for Neuroendocrine Cancers
The clock is ticking!! With Advanced Accelerator Applications’ completed New Drug Application (NDA) submission of Lutathera to the U.S. Food and Drug Administration last week, a decision from the FDA is expected by early 2017. Additionally, an Expanded…
READ MORE
15 Videos from the 3rd Theranostics World Congress
The 3rd Theranostics World Congress featured a patient education day on Saturday, March 14, made possible with support from the Carcinoid Cancer Foundation and the Caring for Carcinoid Foundation. The NorCal CarciNET Community provided funding to…
READ MORE
3rd Theranostics World Congress Offers Free Patient Program on March 14
Johns Hopkins University in Baltimore, Maryland will be the site of the 3rd Theranostics World Congress on Ga-68 & PRRT from March 12-14, 2015. Co-sponsored by the Society of Nuclear Medicine and Molecular Imaging and Johns Hopkins Medicine, the…
READ MORE
Josh Mailman’s Patient Perspective on Integrative Oncology
“A Patient’s Perspective on Integrative Oncology: Getting Past the ‘War,’ Living with and Beyond Cancer” by Josh Mailman has been published in the November 2014 issue of the Journal of the National Cancer Institute Monographs focused on Integrative…
READ MORE
Neuroendocrine Tumors Featured in Society of Nuclear Medicine and Molecular Imaging 2014 Meeting
Josh Mailman, President of the NorCal CarciNET Community and Chair of the Patient Advocacy Advisory Board for the Society of Nuclear Medicine and Molecular Imaging (SNMMI), will give the Welcome presentation for the SNMMI Patient Education Day on June…
READ MORE
10 Highlights of the Year 2013 for the Carcinoid and Neuroendocrine Tumor Community
As the Carcinoid Cancer Foundation looks back on the year 2013, we reached out to physicians, patients, support group leaders, listserv managers, patient advocates, and business colleagues to see what they thought were among the highlights of the past…
READ MORE
Neuroendocrine Tumors Featured in Society of Nuclear Medicine and Molecular Imaging Patient Program
Josh Mailman, President of the NorCal CarciNET support group and Chair of the Patient Advocate Advisory Board for the Society of Nuclear Medicine and Molecular Imaging (SNMMI), will give the Welcome presentation for the SNMMI Patient Education Day …
READ MORE
